Tarrytown, NY-Based Drug Co Regeneron Pharmaceuticals Was Required to Make a $326 Mil Income Tax Expense Charge in the 4Q 2017 Due to the Loss in Value of Its Deferred Income Tax Assets Caused By the US Trump Tax Bill